A Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques
Viruses · 2024
DOI: 10.3390/v16121934 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Elizabeth E Zumbrun und 39 weiteren Autor:innen. Beteiligte Einrichtung: United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA. Hauptthemen laut MEDLINE: Macaca mulatta, Adenosine Monophosphate, Hemorrhagic Fever, Ebola, Alanine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Studies at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) were supported by the Joint Program Executive Office for Chemical, Biolog…, Joint Program Executive Office for Chemical, Biological, Radiological.
Abstract (Originalsprache)
Ebola virus (EBOV) causes severe disease in humans, with mortality as high as 90%. The small-molecule antiviral drug remdesivir (RDV) has demonstrated a survival benefit in EBOV-exposed rhesus macaques. Here, we characterize the efficacy of multiple intravenous RDV dosing regimens on survival of rhesus macaques 42 days after intramuscular EBOV exposure. Thirty rhesus macaques underwent surgical implantation of telemetry devices for the fine-scale monitoring of body temperature and activity, as well as central venous catheters, to enable treatment administration and blood collection. Treatment, consisting of a loading dose of RDV followed by once-daily maintenance doses for 11 days, was initiated 4 days after virus exposure when all animals were exhibiting disease signs consistent with incipient EBOV disease as well as quantifiable levels of EBOV RNA in plasma. In the RDV treatment groups receiving loading/maintenance doses of 5/2.5 mg/kg, 10/5 mg/kg, and 20/10 mg/kg, a total of 6 of 8 (75%), 7 of 8 (87.5%), and 5 of 7 (71.4%) animals survived, respectively. In the vehicle control group, one of seven animals (14.3%) survived. The improved survival rate compared to the control group was statistically significant only for the 10/5 mg/kg RDV treatment group. This treatment regimen also resulted in a significantly lower systemic viral load compared to the vehicle control after a single RDV treatment. All three RDV regimens produced a significantly lower systemic viral load after two treatments. For most animals, RDV treatment, regardless of dose, resulted in the amelioration of many of the clinical–pathological changes associated with EBOV disease in this model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- United States Army Medical Research Institute of Infectious Diseases, Frederick, MD 21702, USA.
- Geneva Foundation, Tacoma, WA 98402, USA.
- PharPoint Research, Inc., Wilmington, NC 28401, USA.
- Labcorp Early Development Laboratories, Madison, WI 53704, USA.
- Gilead Sciences, Inc., Foster City, CA 94404, USA.
ORCID-Profile: Alexandra N Jay, Sarah L Norris, Darius Babusis
Förderung
- Studies at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) were supported by the Joint Program Executive Office for Chemical, Biolog…
- Joint Program Executive Office for Chemical, Biological, Radiological
Zitieren
APA
Zumbrun, E. E., Garvey, C. B., Wells, J. B., Lynn, G. C., Van Tongeren, S. A., Steffens, J. T., Wetzel, K. S., Wetzel, D. L., Esham, H. L., Garza, N. L., Lee, E. D., Scruggs, J. L., Rossi, F. D., Brown, E. S., Weidner, J. M., Gomba, L. M., O'Brien, K. A., Jay, A. N., Zeng, X., …, & Bannister, R. (2024). A Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques. Viruses. https://doi.org/10.3390/v16121934
Vancouver
Zumbrun EE, Garvey CB, Wells JB, Lynn GC, Van Tongeren SA, Steffens JT, et al. A Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques. Viruses. 2024. doi:10.3390/v16121934
BibTeX
@article{Zumbrun2024,
author = {Zumbrun, Elizabeth E and Garvey, Carly B and Wells, Jay B and Lynn, Ginger C and Van Tongeren, Sean A and Steffens, Jesse T and Wetzel, Kelly S and Wetzel, Darrell L and Esham, Heather L and Garza, Nicole L and Lee, Eric D and Scruggs, Jennifer L and Rossi, Franco D and Brown, Elizabeth S and Weidner, Jessica M and Gomba, Laura M and O'Brien, Kristan A and Jay, Alexandra N and Zeng, Xiankun and Akers, Kristen S and Kallgren, Paul A and Englund, Ethan and Meinig, J Matthew and Kugelman, Jeffrey R and Moore, Joshua L and Bloomfield, Holly A and Norris, Sarah L and Bryan, Tameka and Scheuerell, Christie H and Walters, Jesse and Mollova, Nevena and Blair, Christiana and Babusis, Darius and Cihlar, Tomas and Porter, Danielle P and Singh, Bali and Hedskog, Charlotte and Bavari, Sina and Warren, Travis K and Bannister, Roy},
title = {A Randomized, Blinded, Vehicle-Controlled Dose-Ranging Study to Evaluate and Characterize Remdesivir Efficacy Against Ebola Virus in Rhesus Macaques},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16121934}
}
EUVIMED